1,4-Pentanediamine,N4-(6-chloro-2-methoxy-9-acridinyl)-N1,N1-diethyl-, hydrochloride (1:2) cas no:69-05-6

Name1,4-Pentanediamine,N4-(6-chloro-2-methoxy-9-acridinyl)-N1,N1-diethyl-, hydrochloride (1:2)
CAS69-05-6
Synonyms1,4-Pentanediamine,N4-(6-chloro-2-methoxy-9-acridinyl)-N1,N1-diethyl-, dihydrochloride (9CI);Acridine, 6-chloro-9-[[4-(diethylamino)-1-methylbutyl]amino]-2-methoxy-,dihydrochloride (8CI); 2-Chloro-5-(w-diethylamino-a-methylbutylamino)-7-methoxyacridine dihydrochloride;2-Methoxy-6-chloro-9-(4-diethylamino-1-methylbutylamino)acridinedihydrochloride;3-Chloro-7-methoxy-9-(1-methyl-4-diethylaminobutylamino)acridinedihydrochloride;3-Chloro-9-(4'-diethylamino-1'-methylbutylamino)-7-methoxyacridinedihydrochloride; 6-Chloro-9-[[4-(diethylamino)-1-methylbutyl]amino]-2-methoxyacridinedihydrochloride; 866RP; Acrichin dihydrochloride; Atabrine hydrochloride;Atebrin; Atebrine; Atebrine hydrochloride; Chemiochin; Chinacrin hydrochloride;Crinodora; Erion; Malaricida; Mecryl; Mepacrine dihydrochloride; Mepacrine hydrochloride;Methoquine; Metochin; Metoquin; Metoquine; NSC 14229; Palacrin; Palusan;Pentilen; Quinacrine dihydrochloride; Quinacrine hydrochloride; SN 390
EINECS(EC#)200-700-8
Molecular FormulaC23H30 Cl N3 O . 2 Cl H
Molecular Weight472.93

Appearanceyellow crystals or powder

Hazard Xn
Risk 22-36/37/38
Safety

Poison by ingestion, subcutaneous, intrauterine, intravenous, and intraperitoneal routes. Human reproductive effects by intrauterine and intracervical routes: changes in fertility and unspecified effects on the uterus, cervix and vagina. Experimental reproductive effects. Mutation data reported. Used as a treatment for parasitic worms. When heated to decomposition it emits very toxic fumes of Cl⁻ and NO_x.
Safety Information of 6-Chloro-9-((4-(diethylamino)-1-methylbutyl)amino)-2-methoxyacridine dihydrochloride (CAS NO.69-05-6):
Hazard Codes: Xn
Risk Statements: 22-36/37/38 
22:  Harmful if swallowed
36:  Irritating to the eyes 
37:  Irritating to the respiratory system 
38:  Irritating to the skin 
Safety Statements: 36/37/39
36:  Wear suitable protective clothing  
37:  Wear suitable gloves 
39:  Wear eye/face protection 

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
cat	LDLo	intravenous	10mg/kg (10mg/kg)	SENSE ORGANS AND SPECIAL SENSES: MYDRIASIS (PUPILLARY DILATION): EYE BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD GASTROINTESTINAL: CHANGES IN STRUCTURE OR FUNCTION OF SALIVARY GLANDS	Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 170, Pg. 328, 1933.
cat	LDLo	oral	200mg/kg (200mg/kg)	BEHAVIORAL: EXCITEMENT GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" GASTROINTESTINAL: OTHER CHANGES	Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 170, Pg. 328, 1933.
cat	LDLo	subcutaneous	100mg/kg (100mg/kg)	GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" KIDNEY, URETER, AND BLADDER: OTHER CHANGES LIVER: OTHER CHANGES	Naunyn-Schmiedeberg's Archiv fuer Experimentelle Pathologie und Pharmakologie. Vol. 170, Pg. 328, 1933.
dog	LDLo	intravenous	20mg/kg (20mg/kg)	PERIPHERAL NERVE AND SENSATION: FLACCID PARALYSIS WITHOUT ANESTHESIA (USUALLY NEUROMUSCULAR BLOCKAGE) VASCULAR: OTHER CHANGES LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES	Journal of the American Pharmaceutical Association, Scientific Edition. Vol. 34, Pg. 20, 1945.
gerbil	LDLo	intraperitoneal	70mg/kg (70mg/kg)		Contraception. Vol. 17, Pg. 231, 1978.
guinea pig	LD50	intravenous	14mg/kg (14mg/kg)	BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Journal of Pharmacology and Experimental Therapeutics. Vol. 91, Pg. 157, 1947.
hamster	LDLo	intraperitoneal	80mg/kg (80mg/kg)		Contraception. Vol. 17, Pg. 231, 1978.
man	TDLo	oral	34mg/kg/8D-I (34mg/kg)	BEHAVIORAL: TOXIC PSYCHOSIS	Southern Medical Journal. Vol. 75, Pg. 359, 1982.
monkey	LDLo	intravenous	15mg/kg (15mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION	Contraception. Vol. 24, Pg. 269, 1981.
mouse	LD50	intraperitoneal	189mg/kg (189mg/kg)		Journal of Pharmacology and Experimental Therapeutics. Vol. 91, Pg. 133, 1947.
mouse	LD50	intravenous	38mg/kg (38mg/kg)	BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Journal of Pharmacology and Experimental Therapeutics. Vol. 91, Pg. 157, 1947.
mouse	LD50	oral	557mg/kg (557mg/kg)		Journal of Pharmacology and Experimental Therapeutics. Vol. 91, Pg. 157, 1947.
mouse	LD50	subcutaneous	212mg/kg (212mg/kg)	LUNGS, THORAX, OR RESPIRATION: RESPIRATORY DEPRESSION	Annals of Biochemistry and Experimental Medicine. Vol. 1, Pg. 317, 1941.
rabbit	LD50	intravenous	9mg/kg (9mg/kg)	BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)	Journal of Pharmacology and Experimental Therapeutics. Vol. 91, Pg. 157, 1947.
rabbit	LD50	oral	433mg/kg (433mg/kg)		Journal of Pharmacology and Experimental Therapeutics. Vol. 91, Pg. 157, 1947.
rat	LD50	intrauterine	100mg/kg (100mg/kg)		Indian Journal of Experimental Biology. Vol. 16, Pg. 1074, 1978.
rat	LD50	intravenous	29mg/kg (29mg/kg)	BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	Journal of Pharmacology and Experimental Therapeutics. Vol. 91, Pg. 157, 1947.
rat	LD50	oral	660mg/kg (660mg/kg)		Journal of Pharmacology and Experimental Therapeutics. Vol. 91, Pg. 157, 1947.
women	TDLo	oral	18mg/kg/3D-I (18mg/kg)	BEHAVIORAL: TOXIC PSYCHOSIS	Southern Medical Journal. Vol. 75, Pg. 359, 1982.